Monday, 13 November | 13:40 - 15:50
Marie Kosco-Vilbois, Ph.D., CSO, NovImmune SA
Safety Considerations for Development of Immune Agonist and Immune Antagonist Biotherapeutics
Rakesh Dixit, Ph.D., DABT, Vice President, R&D, and Global Head, Biologics Safety Assessment,
MedImmune (A member of AstraZeneca Group)
In this keynote presentation, the challenges of biotherapeutics impacting on the immune response, and the challenges investigators face managing, dose, scheduling, and satisfying the regulatory requirements will be discussed. The checkpoint pathways modulation used for cancer immunotherapy has a natural role in controlling autoimmune diseases such as Type 1 Diabetes and Lupus. Immunotherapies in general, and technologies modifying T cell function and those involving cytokines present dangers of cytokine storm, autoimmune disease, cardiovascular disorders, and additional challenges, especially when used in combination. Strategies to manage and mitigate immune related safety events will be presented.
Learning What Works from Successful Tumour Infiltrating Lymphocyte Therapy
Andrew Sewell, Ph.D., Professor, Division of Infection and Immunity, Cardiff University School of Medicine
Over 20% of melanoma patients that have been refractory to other treatments undergo complete lasting remission after adoptive cell transfer of tumor-infiltrating lymphocytes (TILs). Dissection of these extraordinary successes by examining the dominant tumor-reactive T-cell clonotypes in the TIL infusion product and patient blood after 'cure' has revealed some surprising, exciting new HLA-restricted and non-HLA restricted targets that are expressed by many other tumour types.
Widening the Therapeutic Index: The Next Generation of Antibody-Drug Conjugates (ADCs)
John Lambert, Ph.D., Executive Vice President and Distinguished Research Fellow, ImmunoGen, Inc.
ADCs with potent tubulin-acting and DNA-acting agents can be effective anti-cancer agents with good TI. However, not all cell-surface targets have proven susceptible to the development of effective ADCs utilizing the first generation ADC chemistries. Each element in the ADC design, the antibody, the payload, and the linker (both site of attachment on antibody and payloadrelease mechanism) are important considerations. Application of the growing "ADC Toolbox" to current and future ADC developments will be discussed.